【Abstract】 Background and objective Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. This article analyzed the efficacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC. Methods We retrospectively analyzed the short-term efficacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. Results Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). The overall response rate was 5.9%, and the disease control rate was 47.1%. The median progression-free survival was 4.4 months (95%CI: 4.05-7.46). The main grade 3/4 toxicity was hand-foot skin reaction. Conclusion Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.
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P<0.05）；在血清蛋白分子标志物检测中，发现类似
sVEGFR-3、sVEGFR-2以及VEGFC水平的变化与舒尼替
尼疗效的相关性， 譬如90%疾病获得控制的患者基础血浆
sVEGFR-3水平<51,200 pg/mL。其他实体瘤的临床研究 [17] 中也验证了sVEGFR-3有可能成为抗血管生成的酪氨酸激 www.lungca.org
